A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines-Reference-Cited by-同舟云学术

A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines

Published:2022-04 Issue:18 Volume:40 Page:2551-2560
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Nanthapisal Sira,Puthanakit Thanyawee,Jaru-Ampornpan Peera,Nantanee Rapisa^ORCID,Sodsai Pimpayao,Himananto Orawan,Sophonphan Jiratchaya,Suchartlikitwong Pintip,Hiransuthikul Narin,Angkasekwinai Pornpimon,Tangsathapornpong Auchara,Hirankarn Nattiya

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference31 articles.

1. WHO. WHO Coronavirus (COVID-19) Dashboard [Available from: https://covid19.who.int/. Accessed date 20 January, 2022.

2. WHO. COVID-19 Weekly Epidemiological Update Edition 68, published 30 November 2021 2021 [Available from: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---30-november-2021. Accessed date 7 December, 2021.

3. Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants;Edara;N Engl J Med,2021

4. WHO. Interim statement on COVID-19 vaccine booster doses 2021 [updated 10 August 2021. Available from: https://www.who.int/news/item/10-08-2021-interim-statement-on-covid-19-vaccine-booster-doses. Accessed date 29 August, 2021.

5. Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile;Jara;N Engl J Med,2021

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Equal Maintenance of Anti-SARS-CoV-2 Antibody Levels Induced by Heterologous and Homologous Regimens of the BNT162b2, ChAdOx1, CoronaVac and Ad26.COV2.S Vaccines: A Longitudinal Study Up to the 4th Dose of Booster;Vaccines;2024-07-18

2. Effect of homologous or heterologous vaccine booster over two initial doses of inactivated COVID-19 vaccine;Expert Review of Vaccines;2024-02-27

3. Comparing reactogenicity of COVID-19 vaccine boosters: a systematic review and meta-analysis;Expert Review of Vaccines;2024-02-26

4. Immunogenicity of BNT162b2 in children 6 months to under 5 years of age with previous SARS-CoV-2 infection, in the era of Omicron predominance;Vaccine: X;2023-12

5. Long-term immunogenicity in previously vaccinated healthcare workers with inactivated virus vaccine after SARS-CoV-2 infection or booster vaccination;Vaccine: X;2023-08